BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Mobinitinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Mobinitinib\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04581512-2903@assetmemo.bio
DTSTAMP:20261121T004505Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Mobinitinib: Phase 1/2 readout est. (NCT04581512)
DESCRIPTION:Mobinitinib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Study
  to Evaluate the Safety and Tolerability of EP0042\nEstimated primary comp
 letion: December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/mobinitinib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT04581512
URL:https://assetmemo.bio/drug/mobinitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
